Bristol-Myers Squibb Company Profile (NYSE:BMY)

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb (NYSE:BMY) (?)
Ratings Breakdown: 2 Sell Rating(s), 7 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $73.54 (2.83% downside)

Analysts' Ratings History for Bristol-Myers Squibb (NYSE:BMY)
Show:
DateFirmActionRatingPrice TargetActions
7/14/2016Jefferies GroupBoost Price TargetHold$77.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Berenberg BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Deutsche Bank AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2016Hilliard LyonsInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016ArgusReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Credit Suisse Group AGBoost Price TargetOutperform$75.00 -> $79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016Barclays PLCBoost Price TargetEqual Weight$70.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Societe GeneraleInitiated CoverageSell$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Sanford C. BernsteinBoost Price TargetMarket Perform$67.00 -> $69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$74.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/14/2015Cowen and CompanyReiterated RatingOutperform$75.00 -> $100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2015Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/24/2015Piper Jaffray Cos.UpgradeUnderweight -> Neutral$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/28/2014FBR & CoReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014MKM PartnersBoost Price TargetSell$34.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Bristol-Myers Squibb (NYSE:BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016Q216$0.66$4.60 billionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2015Q414$0.41$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2012$0.42$0.41ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2012$0.48$0.48ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.64$0.64ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2012$0.55$0.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$0.58$0.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.55$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011$0.53$0.58ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$0.48$0.47ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bristol-Myers Squibb (NYSE:BMY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.63$0.66$0.64
Q2 20164$0.65$0.69$0.67
Q3 20163$0.61$0.64$0.63
Q4 20163$0.57$0.64$0.60
Q1 20171$0.74$0.74$0.74
Q2 20171$0.80$0.80$0.80
Q3 20171$0.84$0.84$0.84
Q4 20171$0.86$0.86$0.86
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Bristol-Myers Squibb (NYSE:BMY)
Annual Dividend:$1.52
Dividend Yield:2.01%
Payout Ratio:156.70% (Based on Trailing 12 Months of Earnings)
58.69% (Based on Current Year Consensus EPS Estimate)
46.91% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.90% (3 Year Average)

Dividend History for Bristol-Myers Squibb (NYSE:BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016Tweet This Announcement  Share This Announcement on StockTwits
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016Tweet This Announcement  Share This Announcement on StockTwits
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015Tweet This Announcement  Share This Announcement on StockTwits
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015Tweet This Announcement  Share This Announcement on StockTwits
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015Tweet This Announcement  Share This Announcement on StockTwits
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014Tweet This Announcement  Share This Announcement on StockTwits
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014Tweet This Announcement  Share This Announcement on StockTwits
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014Tweet This Announcement  Share This Announcement on StockTwits
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013Tweet This Announcement  Share This Announcement on StockTwits
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013Tweet This Announcement  Share This Announcement on StockTwits
12/4/2012quarterly$0.351/4/20132/1/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bristol-Myers Squibb (NYSE:BMY)
DateHeadline
07/24/16 07:35 AMThis Global Specialty Biopharmaceutical Company Looks Potentially Strong
07/23/16 02:49 PMThe Key Numbers To Watch From Bristol-Myers Squibb Company (NYSE:BMY)'s Earnings - The Voice Registrar
07/23/16 07:13 AMFriday Session Wrap-up for Bristol-Myers Squibb Company (NYSE:BMY) - Engelwood Daily
07/22/16 02:57 PMBristol-Myers Squibb Company (NYSE:BMY) Fell -0.29%: Sprint Corporation (NYSE:S), Genocea Biosciences, Inc ... - KC Register
07/22/16 02:57 PMEarnings at a Glance: Bristol-Myers Squibb Company (NYSE:BMY), Crown Holdings, Inc. (NYSE:CCK), Univar Inc ... - Engelwood Daily
07/22/16 02:57 PMStocks Analysts Ranking Summary: Bristol-Myers Squibb (NYSE:BMY) , WellCare Health Plans, Inc. (NYSE:WCG) - Street Updates
07/22/16 02:57 PMPrivate Trust Co Na Lowers stake in Bristol-Myers Squibb Co (BMY) - TheFounders Daily
07/22/16 10:19 AMWill Q2 Earnings Hold a Surprise for Nielsen (NLSN) Stock? -
07/21/16 08:28 PMHC Stocks News Alert: Bristol-Myers Squibb Co (NYSE:BMY), Mast Therapeutics Inc (NYSEMKT:MSTX) - share market updates (press release)
07/21/16 02:56 PMStock Strength in Focus for Bristol-Myers Squibb Company (NYSE:BMY) - Press Telegraph
07/21/16 02:56 PMHC Stocks Judgment: Bristol-Myers Squibb Co (NYSE:BMY), Horizon Pharma PLC (NASDAQ:HZNP) - share market updates (press release)
07/21/16 02:56 PMHC Stocks Alerts: Bristol-Myers Squibb Co (NYSE:BMY), Celgene Corporation (NASDAQ:CELG) - share market updates (press release)
07/21/16 02:56 PMBristol-Myers Squibb (BMY) Announces Commercial Launch of Orencia ClickJect Autoinjector for RA - StreetInsider.com
07/21/16 02:56 PMOffice Depot Inc (NASDAQ:ODP) & Bristol-Myers Squibb Co (NYSE:BMY) Trend Analysis Report - Money News (press release)
07/20/16 09:48 PMBristol-Myers Squibb launches Orencia ClickJect drug-device combo for rheumatoid arthritis
07/20/16 03:25 PMTop Of Its Game: Bristol-Myers Squibb's Opdivo Is Poised To Break On Through In Head And Neck Cancer
07/20/16 03:25 PMCompany Update: Bristol-Myers Squibb
07/20/16 02:28 PMResMed (RMD) Q4 Earnings: Disappointment in the Cards? -
07/20/16 10:57 AMJim Cramer Shares His Thoughts On Bristol-Myers Squibb And The RNC
07/20/16 10:57 AMBristol-Myers Squibb Launches ORENCIA ClickJect Autoinjector - Quick Facts
07/20/16 10:57 AMBristol-Myers Squibb (BMY) Announces Commercial Launch of Orencia ClickJect Autoinjector for RA
07/20/16 10:57 AMBristol-Myers Squibb Announces Availability of FDA-Approved …
07/20/16 10:39 AMBristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis - [Business Wire] - Bristol-Myers Squibb Company announced today the commercial launch of the ORENCIA ClickJectTM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis .
07/20/16 08:16 AMBristol-Myers Squibb Says FDA-Approved ORENCIA Is Available For Adults With Moderate To Severe Rheumatoid Arthritis - Bristol-Myers Squibb Company (NYSE: BMY) disclosed Wednesday the commercial launch of the FDA-approved ORENCIA ClickJectTM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis (RA). According to the company, the ORENCIA ClickJect delivers 125 mg of subcutaneous (SC) ORENCIA with push button operation, as well as, injection confirmation that ...Full story available on Benzinga.com
07/19/16 08:18 PM$30M Settlement with Bristol-Myers Squibb in California Whistleblower Suit
07/19/16 02:56 PMBristol-Myers Squibb Announces Regulatory Updates for Opdivo (…
07/19/16 09:04 AMStock Positive on the Year: Bristol-Myers Squibb Company (NYSE:BMY) - TGP
07/19/16 09:04 AMAbner Herrman Brock Lowers stake in Bristol-Myers Squibb Co (BMY) - Trade Calls
07/19/16 07:22 AM5 Big Pharma Stocks Struggling to Raise Their Dividends -
07/18/16 02:59 PMBristol-Myers Squibb Company (NYSE:BMY) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 02:59 PMTrading Performance and Target Watch for Bristol-Myers Squibb Company (NYSE:BMY) - Press Telegraph
07/18/16 02:59 PMBristol-Myers Squibb (BMY) Announces FDA, EMA Acceptance of Opdivo Apps for Usage in SCCHN - StreetInsider.com
07/18/16 02:59 PMGoPro Inc (NASDAQ:GPRO) & Bristol-Myers Squibb Co (NYSE:BMY) Are Stocks to Keep Your Eyes on - Money News (press release)
07/18/16 07:51 AMRegulatory apps under review in U.S. and Europe for expanded use of Opdivo
07/18/16 07:51 AMBristol-Myers Announces U.S. And European Submissions For Expanded Use Of Opdivo
07/18/16 07:51 AMBRIEF-Bristol-Myers Squibb- U.S., EU regulators accept application to expand approval for cancer drug, Opdivo
07/18/16 07:51 AMBristol-Myers Squibb Reveals Regulatory Approvals For Opdivo Marketing Application
07/18/16 06:00 AM7:00 am Bristol-Myers announces U.S. & European marketing applications to expand the use of Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head & neck were accepted for filing by the FDA a -
07/18/16 05:59 AMBristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - [Business Wire] - Bristol-Myers Squibb Company announced today U.S. and European marketing applications to expand the use of Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck were accepted for filing by the U.S.
07/17/16 02:45 PMShare Performance Summary for: Bristol-Myers Squibb Company (NYSE:BMY) - Press Telegraph
07/17/16 02:45 PMBristol-Myers Squibb Company (NYSE:BMY): The Buzzing Stock - Stocks Daily
07/16/16 02:51 PMBristol-Myers Squibb (BMY) Shares Cross 2% Yield Mark
07/16/16 07:49 AMBristol-Myers Squibb (BMY) Shares Cross 2% Yield Mark - Nasdaq
07/14/16 02:55 PMWellington Management Group Llp Decreased Stake in Bristol Myers Squibb Co (NYSE:BMY) by $48.97 Million as ... - Consumer Eagle
07/14/16 02:55 PMCrowd Rating and Earnings Recap for Bristol-Myers Squibb Company (NYSE:BMY) - Telanagana Press
07/14/16 12:30 PMAll-time high playbook -
07/14/16 10:58 AMAnalyst Review: Bristol-Myers Squibb Company (NYSE:BMY) - News Oracle
07/14/16 10:58 AMNewman Dignan Sheerar Lowers stake in Bristol-Myers Squibb Co (BMY) - Trade Calls
07/13/16 02:54 PMStock Touching a Recent High: Bristol-Myers Squibb Company (NYSE:BMY) - Press Telegraph
07/13/16 02:54 PMBristol-Myers Squibb Company (NYSE:BMY)'s Growth Projection - RealistInvestor.com

Social

About Bristol-Myers Squibb

Bristol-Myers Squibb logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Its small molecule drugs are administered orally in the form of a pill or tablet. Its biologics are administered to patients through injections or by infusion. It offers products in a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: BMY
  • CUSIP: 11012210
Key Metrics:
  • Previous Close: $75.50
  • 50 Day Moving Average: $73.62
  • 200 Day Moving Average: $67.86
  • P/E Ratio: 81.29
  • P/E Growth: 1.26
  • Market Cap: $126.33B
  • Beta: 0.53
  • Current Year EPS Consensus Estimate: $2.59 EPS
  • Next Year EPS Consensus Estimate: $3.24 EPS
Additional Links:
Bristol-Myers Squibb (NYSE:BMY) Chart for Monday, July, 25, 2016